Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol)

Maruyama, Kazuo; Yuda, Tsutomu; Okamoto, Akiyoshi; Kojima, Shuji; Suginaka, Akinori; Iwatsuru, Motoharu

doi:10.1016/0005-2760(92)90255-t

Cited by 216 publications

(106 citation statements)

References 15 publications

Supporting

Mentioning

104

Contrasting

Order By: Relevance

“…The diameters of the Doxil particles were controlled at around 100 nm (Table 1). A biodistribution analysis showed that uptake by liver and spleen was independent and dependent on the size of liposomes respectively, consistent with previous studies [23,24]. This accounts for the lower blood concentration for the dual-ligand LP compared to Doxil.…”

Section: Comparison Of Dual-ligand With Doxil (Caelyx) ®supporting

confidence: 89%

Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy

Takara

Hatakeyama

Kibria

et al. 2012

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

Section: Comparison Of Dual-ligand With Doxil (Caelyx) ®supporting

confidence: 89%

Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy

Takara

Hatakeyama

Kibria

et al. 2012

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…Previous studies with PEG, or PEG derivatives, coupled to purified proteins have demonstrated that the protein half-life within the circulation is greatly improved (5,6,8). Similarly, liposomes containing externally disposed PEG lipids have improved half-lives in vivo (33)(34)(35). It is also of interest that the covalent attachment of PEG usually does not impair the function of purified enzymes and appears to make foreign proteins nonimmunogenic even after repetitive intravenous administration (5,6,8,(36)(37)(38)(39).…”

Section: Discussionmentioning

confidence: 99%

Chemical camouflage of antigenic determinants: Stealth erythrocytes

Scott

Murad

Koumpouras

et al. 1997

Proc. Natl. Acad. Sci. U.S.A.

208

215

View full text Add to dashboard Cite

In a number of clinical circumstances it would be desirable to artificially conceal cellular antigenic determinants to permit survival of heterologous donor cells. A case in point is the problem encountered in transfusions of patients with rare blood types or chronically transfused patients who become allosensitized to minor blood group determinants. We have tested the possibility that chemical modification of the red blood cell (RBC) membrane might serve to occlude antigenic determinants, thereby minimizing transfusion reactions. To this end, we have covalently bound methoxy(polyethylene glycol) (mPEG) to the surface of mammalian RBC via cyanuric chloride coupling. Human RBC treated with this technique lose ABO blood group reactivity as assessed by solution-phase antisera agglutination. In accord with this, we also find a profound decrease in anti-blood group antibody binding. Furthermore, whereas human monocytes avidly phagocytose untreated sheep RBC, mPEG-derivatized sheep RBC are ineffectively phagocytosed. Surprisingly, human and mouse RBC appear unaffected by this covalent modification of the cell membrane. Thus, mPEG-treated RBC are morphologically normal, have normal osmotic fragility, and mPEG-derivatized murine RBC have normal in vivo survival, even following repeated infusions. Finally, in preliminary experiments, mPEG-modified sheep RBC intraperitoneally transfused into mice show significantly improved (up to 360-fold) survival when compared with untreated sheep RBC. We speculate that similar chemical camouf lage of intact cells may have significant clinical applications in both transfusion (e.g., allosensitization and autoimmune hemolytic disease) and transplantation (e.g., endothelial cells and pancreatic ␤ cells) medicine.The transfusion of red blood cells (RBC) is the most common, and best tolerated, form of tissue transplantation. Indeed, in 1993, over 14 million units of blood were donated for transfusion in the United States alone (1). In most transfusions, simple blood typing (ABO͞Rh-D) is sufficient to identify appropriate donors. Occasionally, however, appropriate donors for patients with rare blood types cannot quickly be found; a situation that may become life-threatening. More often, problems are encountered in individuals who receive chronic transfusions, such as patients with sickle cell anemia and thalassemia. In such patients, alloimmunization against minor RBC antigens can make it nearly impossible to identify appropriate blood donors (2-4). Previous studies in which purified proteins were covalently modified with poly(ethylene glycol) (PEG) provided a possible solution to this problem. PEG-modified proteins have been shown to have increased in vivo survival and to be nonimmunogenic, even with repeated infusions (5, 6). We therefore explored the hypothesis that the covalent binding of PEG to intact RBC might mask RBC surface antigens and thereby permit the survival of heterologous or even xenogeneic RBC.To experimentally test this hypothesis, human, mouse, and sheep RBC were...

show abstract

“…Liposomes containing either monosialoganglioside G M1 (Allen et al, 1989) or polyethylene glycol (PEG) derivatives (Blume and Cevc, 1990;Klibanov et al, 1990;Allen et al, 1991;Maruyama et al, 1992;Woodle and Lasic, 1992;Yuda et al, 1996) are not readily taken up by the macrophages in reticuloendothelial system (RES), and hence remain in the blood circulation for a relatively long period of time. Particularly, PEG-modified liposomes (PEG liposomes) have been utilized as a particulate carrier for anti-tumor therapy due to their long circulation time.…”

Section: Introductionmentioning

confidence: 99%

Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats

Yokoe

Sakuragi

Yamamoto

et al. 2008

International Journal of Pharmaceutics

View full text Add to dashboard Cite

To evaluate the effect of coupling of recombinant human serum albumin (rHSA) onto the surface of poly(ethylene glycol)-modified liposome (PEG liposome) on the in-vivo disposition characteristics of liposomal doxorubicin (DXR), the pharmacokinetics and tissue distribution of DXR were evaluated after intravenous administration of rHSA-modified PEG (rHSA/PEG) liposomal DXR into tumor-bearing rats.rHSA/PEG liposome prepared using a hetero-bifunctional cross-linker, N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP), efficiently encapsulated DXR (over 95%). rHSA/PEG liposomal DXR showed longer blood-circulating property than PEG liposomal DXR and the hepatic and splenic clearances of rHSA/PEG liposomal DXR were significantly smaller than those of PEG liposomal DXR. It was also demonstrated that the disposition of DXR to the heart, one of the organs for DXR-related side-effects, was significantly smaller than free DXR. Furthermore, the tumor accumulation of rHSA/PEG liposomal DXR was significantly larger than that of PEG liposomal DXR. The "therapeutic index", a criterion for therapeutic outcome, for rHSA/PEG liposomal DXR was significantly higher than PEG liposomal DXR. These results clearly indicate that rHSA-conjugation onto the surface of PEG liposome would be a useful approach to increase the effectiveness and safety of PEG liposomal DXR.

show abstract

Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol)

Cited by 216 publications

References 15 publications

Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy

Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy

Chemical camouflage of antigenic determinants: Stealth erythrocytes

Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats

Contact Info

Product

Resources

About